Anastrozole vs Exemestane
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: Aromatase · full HR+/HER2- Metastatic Breast Cancer pipeline
Anastrozole
Marketed by ANI Pharmaceuticals, Inc. and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT07163481 (registry estimate)
Reported efficacy
To assess the difference in event free survival and overall survival (subject to stand-alone or combined/meta-analysis) between postmenopausal women with HR +ve early BC who switched from tamoxifen to anastrozole and those who continued on tamoxifen.: Recurrence-free survival, 2yr tamoxifen then 3yr anastrozole vs 5yr tamoxifen: HR 0.80 (95% CI 0.63-1.01), P=.06 (not statistically significant) (missed)
Result source: NCT00291759
Exemestane
Marketed by Pfizer
NCT00002777 · Phase 3 · completed
The study used randomization and an active tamoxifen comparator with an estimated sample size of 342 participants. The registry record gives no statistical test for the primary comparison; the key result shown reports it from the cited source. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: December 2026 · NCT07163481 (registry estimate)
Reported efficacy
Objective response rate: 46% exemestane vs 31% tamoxifen (odds ratio 1.85, 95% CI 1.21-2.82, P=.005). Median progression-free survival (the trial's primary endpoint): 9.9 months exemestane vs 5.8 months tamoxifen; long-term log-rank P=.121 (not statistically significant). (missed)
Result source: NCT00002777
Results for HR+/HER2- Metastatic Breast Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Anastrozole | Exemestane |
|---|---|---|
| PFS, median | 4.8 vs 2.4vs AnastrozoleNCT0002267210 other results
| 7.3 vs 10vs CapecitabineNCT0202850714 other results
|
| OS, median | 20.2 vs 22.5vs ExemestaneNCT002534224 other results
| 33.7 vs 32vs CapecitabineNCT020285077 other results
|
| ORR | 45.3%bNCT038224682 other results
| 14.3%bNCT017435606 other results
|
| Clinical benefit rate | 42.7% vs 27.9%vs AnastrozoleNCT000226723 other results
| 48.2%bNCT0317623810 other results
|
PFS, median
- Anastrozole
- 4.8 vs 2.4vs AnastrozoleNCT00022672
10 other results
- 4.1 vs 3.5 NCT00253422
- 21.8 vs 12.8 NCT03839823
- 21 NCT00405938
- 9 NCT00405938
- 25.1 NCT03822468
- 26.9 NCT03822468
- 3.1 NCT01791985
- 5.2 NCT02648477
- 1.8 NCT02648477
- 2 NCT01720602
- Exemestane
- 7.3 vs 10vs CapecitabineNCT02028507
14 other results
- 3.5 NCT00253422
- 8 vs 10.6 NCT02028507
- 9.4 NCT03176238
- 8.5 NCT03176238
- 4.2 vs 3.7 NCT00767520
- 3.6 vs 3.7 NCT01381874
- 4.5 vs 3.7 NCT01381874
- 4.3 NCT00810797
- 7.9 vs 6.7 NCT02258451
- 4.1 NCT02049957
- 3.3 NCT02049957
- 5.5 NCT01743560
- 5.2 NCT02648477
- 1.8 NCT02648477
OS, median
- Anastrozole
- 20.2 vs 22.5vs ExemestaneNCT00253422
4 other results
- 28.5 vs 23.9 NCT00022672
- 15.6 NCT02648477
- 17.2 NCT02648477
- 19 NCT01720602
- Exemestane
- 33.7 vs 32vs CapecitabineNCT02028507
7 other results
- 22.5 NCT00253422
- 26.4 NCT01381874
- 25 vs 26.4 NCT02258451
- 15.9 NCT02049957
- 14 NCT02049957
- 15.6 NCT02648477
- 17.2 NCT02648477
ORR
- Anastrozole
- 45.3%bNCT03822468
2 other results
- 41.5% NCT03822468
- 66.1% vs 61.8% NCT03839823
- Exemestane
- 14.3%bNCT01743560
6 other results
- 6.1% vs 0% NCT00767520
- 5.8% vs 6.3% NCT01381874
- 12.1% vs 6.3% NCT01381874
- 7% NCT02049957
- 0% NCT02049957
- 8.3% NCT00810797
Clinical benefit rate
- Anastrozole
- 42.7% vs 27.9%vs AnastrozoleNCT00022672
3 other results
- 81.3% vs 74.5% NCT03839823
- 50% NCT02648477
- 20% NCT02648477
- Exemestane
- 48.2%bNCT03176238
10 other results
- 30.6% NCT03176238
- 44% NCT02049957
- 23% NCT02049957
- 30.6% vs 12.2% NCT00767520
- 9.6% vs 12.7% NCT01381874
- 22.7% vs 12.7% NCT01381874
- 28% NCT02049957
- 23% NCT02049957
- 50% NCT02648477
- 20% NCT02648477
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
10 other shared endpoints and safety
Coverage. Anastrozole: 14 of 14 rows · Exemestane: 14 of 14 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Anastrozole Rows use multiple source trials | Exemestane Rows use multiple source trials |
|---|---|---|
| Clinical Benefit event count · % of participants | 28.3% (n=233) vs 23.8% (n=239) Exemestane*a,b NCT00253422 · Phase 3 · registry result, not featured evidence · combination · converted to % from 66 Participants as posted | 76.2% (n=206) vs 82.4% (n=187) Capecitabine*a,b NCT02028507 · Phase 3 · registry result, not featured evidence · combination · converted to % from 157 Participants as posted |
| Clinical Benefit event count · % of participants No placebo or comparator arm | 70.7% (n=188)*600 mgc,d,a,e,b NCT03822468 · Phase 2 · registry result, not featured evidence · converted to % from 133 Participants as posted show 1 more dose75.5% (n=188)*400 mg NCT03822468 · Phase 2 · registry result, not featured evidence · converted to % from 142 Participants as posted | 23.8% (n=239)*d,a,e,b NCT00253422 · Phase 3 · registry result, not featured evidence · converted to % from 57 Participants as posted |
| Clinical Benefit responder rate · % of participants No placebo or comparator arm | 50% (n=10)c,d,f,b NCT02648477 · Phase 2 · registry result, not featured evidence · combination show 1 more dose20% (n=20) NCT02648477 · Phase 2 · registry result, not featured evidence · combination | 48.2% (n=199)c,d,f,b NCT03176238 · Phase 3 · registry result, not featured evidence · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 show 1 more dose30.6% (n=36) NCT03176238 · Phase 3 · registry result, not featured evidence · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 |
| Duration of Response time to event · months | 8.7 vs 12.8 Exemestane monthsa,b NCT00253422 · Phase 3 · registry result, not featured evidence · combination 2 other source trials9.5 vs 10 Anastrozole months @ 104wk NCT00022672 · Phase 3 · registry result, not featured evidence · combination 12.3 vs 8.2 Anastrozole months NCT00022672 · Phase 3 · registry result, not featured evidence · combination | 9.7 vs 11.2 Capecitabine monthsa,b NCT02028507 · Phase 3 · registry result, not featured evidence · combination 2 other source trials6.93 vs 6.47 Exemestane months @ 104wk NCT01381874 · Phase 2 · registry result, not featured evidence · combination 4.86 vs 6.47 Exemestane months @ 104wk NCT01381874 · Phase 2 · registry result, not featured evidence · combination |
| Duration of Response time to event · months No placebo or comparator arm | 28.8 months600 mgc,d,a,e,b NCT03822468 · Phase 2 · registry result, not featured evidence show 1 more dose26.5 months400 mg NCT03822468 · Phase 2 · registry result, not featured evidence | 12.8 monthsd,a,e,b NCT00253422 · Phase 3 · registry result, not featured evidence |
| ORR event count · % of participants | 7.3% (n=233) vs 4.2% (n=239) Exemestane*a,b NCT00253422 · Phase 3 · registry result, not featured evidence · combination · converted to % from 17 Participants as posted | 22.8% (n=206) vs 29.4% (n=187) Capecitabine*a,b NCT02028507 · Phase 3 · registry result, not featured evidence · combination · converted to % from 47 Participants as posted |
| ORR responder rate · % of participants No placebo or comparator arm | 45.3% (n=188)600 mgc,g,a,e,b NCT03822468 · Phase 2 · registry result, not featured evidence show 1 more dose41.5% (n=188)400 mg NCT03822468 · Phase 2 · registry result, not featured evidence | 14.3% (n=49) @ 48wkg,a,e,b NCT01743560 · Phase 4 · registry result, not featured evidence · combination 3 other source trials8.3% (n=36) NCT00810797 · Phase 2 · registry result, not featured evidence 0% (n=35)4 mg + Exemestane NCT02049957 · Phase 2 · registry result, not featured evidence · combination 7% (n=43)4 mg + Exemestane NCT02049957 · Phase 2 · registry result, not featured evidence · combination |
| ORR event count · % of participants No placebo or comparator arm | 50% (n=10)*c,d,a,e,b NCT02648477 · Phase 2 · registry result, not featured evidence · combination · converted to % from 5 Participants as posted show 1 more dose10% (n=20)* NCT02648477 · Phase 2 · registry result, not featured evidence · combination · converted to % from 2 Participants as posted | 4.2% (n=239)*d,a,e,b NCT00253422 · Phase 3 · registry result, not featured evidence · converted to % from 10 Participants as posted 2 other source trials50% (n=10)* NCT02648477 · Phase 2 · registry result, not featured evidence · combination · converted to % from 5 Participants as posted 10% (n=20)* NCT02648477 · Phase 2 · registry result, not featured evidence · combination · converted to % from 2 Participants as posted |
| Overall Survival time to event · months No placebo or comparator arm | 15.6 monthsc,d,a,e,b NCT02648477 · Phase 2 · registry result, not featured evidence · combination show 1 more dose17.2 months NCT02648477 · Phase 2 · registry result, not featured evidence · combination | 22.5 monthsd,a,e,b NCT00253422 · Phase 3 · registry result, not featured evidence 4 other source trials15.6 months NCT02648477 · Phase 2 · registry result, not featured evidence · combination 17.2 months NCT02648477 · Phase 2 · registry result, not featured evidence · combination 14 months4 mg + Exemestane NCT02049957 · Phase 2 · registry result, not featured evidence · combination 15.9 months4 mg + Exemestane NCT02049957 · Phase 2 · registry result, not featured evidence · combination |
| PFS time to event · months No placebo or comparator arm | 25.1 months600 mgc,g,a,e,b NCT03822468 · Phase 2 · registry result, not featured evidence show 1 more dose26.9 months400 mg NCT03822468 · Phase 2 · registry result, not featured evidence | 5.45 months @ 48wk*g,a,e,b NCT01743560 · Phase 4 · registry result, not featured evidence · combination · converted to months from 23.6 weeks as posted 8 other source trials3.5 months NCT00253422 · Phase 3 · registry result, not featured evidence 9.37 months* NCT03176238 · Phase 3 · registry result, not featured evidence · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 · converted to months from 40.6 weeks as posted 8.54 months* NCT03176238 · Phase 3 · registry result, not featured evidence · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 · converted to months from 37 weeks as posted 5.2 months NCT02648477 · Phase 2 · registry result, not featured evidence · combination 1.8 months NCT02648477 · Phase 2 · registry result, not featured evidence · combination 4.3 months NCT00810797 · Phase 2 · registry result, not featured evidence 3.3 months4 mg + Exemestane NCT02049957 · Phase 2 · registry result, not featured evidence · combination 4.1 months4 mg + Exemestane NCT02049957 · Phase 2 · registry result, not featured evidence · combination |
| Dropout rate | 0%h NCT00253422 · Phase 3 · registry result, not featured evidence · combination show 20 more results84.5% NCT00022672 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestone600 mg NCT03822468 · Phase 2 · registry result, not featured evidence —600mg NCT03822468 · Phase 2 · registry result, not featured evidence n/a: no completion milestone400 mg NCT03822468 · Phase 2 · registry result, not featured evidence —400mg NCT03822468 · Phase 2 · registry result, not featured evidence 0%Cohort 1 (Pembrolizumab, Doxorubic NCT02648477 · Phase 2 · registry result, not featured evidence · combination 0%Cohort 2 (Pembrolizumab, Anti-estr NCT02648477 · Phase 2 · registry result, not featured evidence · combination 68.8%600 mg NCT03839823 · Phase 2 · registry result, not featured evidence —600 mg NCT03839823 · Phase 2 · registry result, not featured evidence 5.6% NCT00570323 · Phase 2 · registry result, not featured evidence · combination 0%Bevacizumab/Anastrozole NCT00405938 · Phase 2 · registry result, not featured evidence · combination 0%Bevacizumab/Fulvestrant NCT00405938 · Phase 2 · registry result, not featured evidence · combination 0%Anastrozole NCT00259090 · Phase 2 · registry result, not featured evidence 0%Fulvestrant + Anastrozole NCT00259090 · Phase 2 · registry result, not featured evidence · combination 15.4% NCT01791985 · Phase 1/2 · registry result, not featured evidence 0% NCT00217399 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination —160 mg + 1 mg NCT01597193 · Phase 1 · registry result, not featured evidence · combination 33.3% NCT01720602 · Phase na · registry result, not featured evidence · combination 0% NCT01004744 · Phase na · registry result, not featured evidence | 29.6%i NCT01176916 · Phase 4 · registry result, not featured evidence show 40 more results—Everolimus + Exemestane NCT01743560 · Phase 4 · registry result, not featured evidence · combination 82.7%Everolimus and Exemestane NCT01743560 · Phase 4 · registry result, not featured evidence · combination 0.4% NCT00253422 · Phase 3 · registry result, not featured evidence n/a: no completion milestone NCT02028507 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestoneAsian Everolimus + Exemestane NCT03176238 · Phase 3 · registry result, not featured evidence · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 n/a: no completion milestoneNon-Asian Everolimus + Exemestane NCT03176238 · Phase 3 · registry result, not featured evidence · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 0% NCT00083174 · Phase 3 · registry result, not featured evidence 0.1% NCT00036270 · Phase 3 · registry result, not featured evidence 0%Cohort 1 (Pembrolizumab, Doxorubic NCT02648477 · Phase 2 · registry result, not featured evidence · combination 0%Cohort 2 (Pembrolizumab, Anti-estr NCT02648477 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone NCT02258451 · Phase 2 · registry result, not featured evidence · combination 0% NCT00810797 · Phase 2 · registry result, not featured evidence 71.7%Abiraterone Acetate + Exemestane + NCT01381874 · Phase 2 · registry result, not featured evidence · combination 70.8%Abiraterone Acetate + Prednisone NCT01381874 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone5 mg + Exemestane NCT02049957 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone4 mg + Exemestane NCT02049957 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone4 mg + Exemestane NCT02049957 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone4 mg + Exemestane NCT02049957 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone3 mg + Exemestane NCT02049957 · Phase 2 · registry result, not featured evidence · combination 0% NCT00201864 · Phase 2 · registry result, not featured evidence · combination 13.9% NCT00767520 · Phase 2 · registry result, not featured evidence · combination 8.7% NCT00073073 · Phase 2 · registry result, not featured evidence — NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination —125mg NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination —100mg NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination —100mg NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination 91.7%80mg bd 1w/1w + Ex 25mg NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination —80mg bd 2w/1w + Ex 25mg NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination 100%80mg bd Cont + Ex 25mg NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination 100%40mg Cont + Ex 25mg NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination —40mg bd Cont + Ex 25mg NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination 100%Part B: AZD4547 + Fulvestrant NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination 0%DOSE FINDING PHASE, Arm A, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 0%DOSE FINDING PHASE, Arm A, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 0%DOSE FINDING PHASE, Arm B, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 0%Dose Finding Phase, Arm C, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 0%Dose Finding Phase, Arm C, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 0%Dose Finding Phase, Arm D, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 0%Dose Finding Phase, Arm D, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 0%Dose Finding Phase, Arm D, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination |
| Discontinued due to AEs | —h NCT00253422 · Phase 3 · registry result, not featured evidence · combination show 20 more results5.8% NCT00022672 · Phase 3 · registry result, not featured evidence · combination 12.8%600 mg NCT03822468 · Phase 2 · registry result, not featured evidence —600mg NCT03822468 · Phase 2 · registry result, not featured evidence 11.2%400 mg NCT03822468 · Phase 2 · registry result, not featured evidence —400mg NCT03822468 · Phase 2 · registry result, not featured evidence —Cohort 1 (Pembrolizumab, Doxorubic NCT02648477 · Phase 2 · registry result, not featured evidence · combination —Cohort 2 (Pembrolizumab, Anti-estr NCT02648477 · Phase 2 · registry result, not featured evidence · combination 7.1%600 mg NCT03839823 · Phase 2 · registry result, not featured evidence —600 mg NCT03839823 · Phase 2 · registry result, not featured evidence — NCT00570323 · Phase 2 · registry result, not featured evidence · combination —Bevacizumab/Anastrozole NCT00405938 · Phase 2 · registry result, not featured evidence · combination —Bevacizumab/Fulvestrant NCT00405938 · Phase 2 · registry result, not featured evidence · combination —Anastrozole NCT00259090 · Phase 2 · registry result, not featured evidence —Fulvestrant + Anastrozole NCT00259090 · Phase 2 · registry result, not featured evidence · combination 13.5% NCT01791985 · Phase 1/2 · registry result, not featured evidence — NCT00217399 · Phase 1/2 · registry result, not featured evidence · combination 14.3%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination —160 mg + 1 mg NCT01597193 · Phase 1 · registry result, not featured evidence · combination 20% NCT01720602 · Phase na · registry result, not featured evidence · combination — NCT01004744 · Phase na · registry result, not featured evidence | 10.8%i NCT01176916 · Phase 4 · registry result, not featured evidence show 40 more results—Everolimus + Exemestane NCT01743560 · Phase 4 · registry result, not featured evidence · combination 15.4%Everolimus and Exemestane NCT01743560 · Phase 4 · registry result, not featured evidence · combination — NCT00253422 · Phase 3 · registry result, not featured evidence 5.2% NCT02028507 · Phase 3 · registry result, not featured evidence · combination —Asian Everolimus + Exemestane NCT03176238 · Phase 3 · registry result, not featured evidence · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 —Non-Asian Everolimus + Exemestane NCT03176238 · Phase 3 · registry result, not featured evidence · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 — NCT00083174 · Phase 3 · registry result, not featured evidence — NCT00036270 · Phase 3 · registry result, not featured evidence —Cohort 1 (Pembrolizumab, Doxorubic NCT02648477 · Phase 2 · registry result, not featured evidence · combination —Cohort 2 (Pembrolizumab, Anti-estr NCT02648477 · Phase 2 · registry result, not featured evidence · combination 11.3% NCT02258451 · Phase 2 · registry result, not featured evidence · combination — NCT00810797 · Phase 2 · registry result, not featured evidence —Abiraterone Acetate + Exemestane + NCT01381874 · Phase 2 · registry result, not featured evidence · combination —Abiraterone Acetate + Prednisone NCT01381874 · Phase 2 · registry result, not featured evidence · combination 16.7%5 mg + Exemestane NCT02049957 · Phase 2 · registry result, not featured evidence · combination 0%4 mg + Exemestane NCT02049957 · Phase 2 · registry result, not featured evidence · combination 17.1%4 mg + Exemestane NCT02049957 · Phase 2 · registry result, not featured evidence · combination 11.6%4 mg + Exemestane NCT02049957 · Phase 2 · registry result, not featured evidence · combination 33.3%3 mg + Exemestane NCT02049957 · Phase 2 · registry result, not featured evidence · combination — NCT00201864 · Phase 2 · registry result, not featured evidence · combination — NCT00767520 · Phase 2 · registry result, not featured evidence · combination — NCT00073073 · Phase 2 · registry result, not featured evidence — NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination —125mg NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination —100mg NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination —100mg NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination 33.3%80mg bd 1w/1w + Ex 25mg NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination —80mg bd 2w/1w + Ex 25mg NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination 40%80mg bd Cont + Ex 25mg NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination 20%40mg Cont + Ex 25mg NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination —40mg bd Cont + Ex 25mg NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination 0%Part B: AZD4547 + Fulvestrant NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination —DOSE FINDING PHASE, Arm A, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination —DOSE FINDING PHASE, Arm A, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination —DOSE FINDING PHASE, Arm B, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination —Dose Finding Phase, Arm C, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination —Dose Finding Phase, Arm C, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination —Dose Finding Phase, Arm D, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination —Dose Finding Phase, Arm D, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination —Dose Finding Phase, Arm D, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination |
| Serious AEs | 16.9%h NCT00253422 · Phase 3 · registry result, not featured evidence · combination show 20 more results24.3% NCT00022672 · Phase 3 · registry result, not featured evidence · combination —600 mg NCT03822468 · Phase 2 · registry result, not featured evidence 19.7%600mg NCT03822468 · Phase 2 · registry result, not featured evidence —400 mg NCT03822468 · Phase 2 · registry result, not featured evidence 20.2%400mg NCT03822468 · Phase 2 · registry result, not featured evidence 30%Cohort 1 (Pembrolizumab, Doxorubic NCT02648477 · Phase 2 · registry result, not featured evidence · combination 10%Cohort 2 (Pembrolizumab, Anti-estr NCT02648477 · Phase 2 · registry result, not featured evidence · combination —600 mg NCT03839823 · Phase 2 · registry result, not featured evidence 15.2%600 mg NCT03839823 · Phase 2 · registry result, not featured evidence 0% NCT00570323 · Phase 2 · registry result, not featured evidence · combination 26.3%Bevacizumab/Anastrozole NCT00405938 · Phase 2 · registry result, not featured evidence · combination 29.3%Bevacizumab/Fulvestrant NCT00405938 · Phase 2 · registry result, not featured evidence · combination 5%Anastrozole NCT00259090 · Phase 2 · registry result, not featured evidence 7.5%Fulvestrant + Anastrozole NCT00259090 · Phase 2 · registry result, not featured evidence · combination 19.2% NCT01791985 · Phase 1/2 · registry result, not featured evidence 34.3% NCT00217399 · Phase 1/2 · registry result, not featured evidence · combination 57.1%1000 mg NCT03099174 · Phase 1 · registry result, not featured evidence · combination 5%160 mg + 1 mg NCT01597193 · Phase 1 · registry result, not featured evidence · combination 13.3% NCT01720602 · Phase na · registry result, not featured evidence · combination 0% NCT01004744 · Phase na · registry result, not featured evidence | 6.8%i NCT01176916 · Phase 4 · registry result, not featured evidence show 40 more results44.9%Everolimus + Exemestane NCT01743560 · Phase 4 · registry result, not featured evidence · combination —Everolimus and Exemestane NCT01743560 · Phase 4 · registry result, not featured evidence · combination 15.6% NCT00253422 · Phase 3 · registry result, not featured evidence 22.7% NCT02028507 · Phase 3 · registry result, not featured evidence · combination —Asian Everolimus + Exemestane NCT03176238 · Phase 3 · registry result, not featured evidence · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 —Non-Asian Everolimus + Exemestane NCT03176238 · Phase 3 · registry result, not featured evidence · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3 1.7% NCT00083174 · Phase 3 · registry result, not featured evidence 17.1% NCT00036270 · Phase 3 · registry result, not featured evidence 30%Cohort 1 (Pembrolizumab, Doxorubic NCT02648477 · Phase 2 · registry result, not featured evidence · combination 10%Cohort 2 (Pembrolizumab, Anti-estr NCT02648477 · Phase 2 · registry result, not featured evidence · combination 43.9% NCT02258451 · Phase 2 · registry result, not featured evidence · combination 11.1% NCT00810797 · Phase 2 · registry result, not featured evidence 26.9%Abiraterone Acetate + Exemestane + NCT01381874 · Phase 2 · registry result, not featured evidence · combination 20.7%Abiraterone Acetate + Prednisone NCT01381874 · Phase 2 · registry result, not featured evidence · combination 16.7%5 mg + Exemestane NCT02049957 · Phase 2 · registry result, not featured evidence · combination 33.3%4 mg + Exemestane NCT02049957 · Phase 2 · registry result, not featured evidence · combination 14.3%4 mg + Exemestane NCT02049957 · Phase 2 · registry result, not featured evidence · combination 25.6%4 mg + Exemestane NCT02049957 · Phase 2 · registry result, not featured evidence · combination 0%3 mg + Exemestane NCT02049957 · Phase 2 · registry result, not featured evidence · combination — NCT00201864 · Phase 2 · registry result, not featured evidence · combination 27.8% NCT00767520 · Phase 2 · registry result, not featured evidence · combination 0% NCT00073073 · Phase 2 · registry result, not featured evidence 25% NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination 100%125mg NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination 83.3%100mg NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination 87.5%100mg NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination 41.7%80mg bd 1w/1w + Ex 25mg NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination 11.1%80mg bd 2w/1w + Ex 25mg NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination 40%80mg bd Cont + Ex 25mg NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination —40mg Cont + Ex 25mg NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination 40%40mg bd Cont + Ex 25mg NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination 20%Part B: AZD4547 + Fulvestrant NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination 0%DOSE FINDING PHASE, Arm A, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 25%DOSE FINDING PHASE, Arm A, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 57.1%DOSE FINDING PHASE, Arm B, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 50%Dose Finding Phase, Arm C, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 33.3%Dose Finding Phase, Arm C, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 0%Dose Finding Phase, Arm D, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 16.7%Dose Finding Phase, Arm D, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination 28.6%Dose Finding Phase, Arm D, Cohort NCT01870505 · Phase 1 · registry result, not featured evidence · combination |
| Most frequent reported AEs | h lethargy 64.5% arthralgia 42% hot flush 37.2% NCT00253422 · Phase 3 · registry result, not featured evidence · combination show 17 more resultsfatigue 21.4% vomiting 20.4% diarrhoea 19.4% NCT00022672 · Phase 3 · registry result, not featured evidence · combination 600mg neutropenia 66.5% leukopenia 27.7% anaemia 26.1% NCT03822468 · Phase 2 · registry result, not featured evidence 400mg neutropenia 53.2% alanine aminotransferase increased 26.1% aspartate aminotransferase increased 21.8% NCT03822468 · Phase 2 · registry result, not featured evidence fatigue 90% nausea 90% white blood cell decreased 90% NCT02648477 · Phase 2 · registry result, not featured evidence · combination fatigue 75% alkaline phosphatase increased 50% aspartate aminotransferase increased 45% NCT02648477 · Phase 2 · registry result, not featured evidence · combination 600 mg neutropenia 65.2% anaemia 35.7% leukopenia 25.9% NCT03839823 · Phase 2 · registry result, not featured evidence hot flashes 32.4% arthralgia 20.6% fatigue 20.6% NCT00570323 · Phase 2 · registry result, not featured evidence · combination fatigue 57.9% hypertension 47.4% pain - head 44.7% NCT00405938 · Phase 2 · registry result, not featured evidence · combination fatigue 73.2% hypertension 48.8% proteinuria 43.9% NCT00405938 · Phase 2 · registry result, not featured evidence · combination hot flush 20% headache 7.5% injection site pain 7.5% NCT00259090 · Phase 2 · registry result, not featured evidence headache 10% pain in extremity 10% hot flush 7.5% NCT00259090 · Phase 2 · registry result, not featured evidence · combination dry mouth 44.2% nausea 40.4% alopecia 38.5% NCT01791985 · Phase 1/2 · registry result, not featured evidence fatigue 65.7% diarrhea 62.9% nausea 60% NCT00217399 · Phase 1/2 · registry result, not featured evidence · combination 1000 mg diarrhoea 85.7% asthenia 71.4% neutropenia 71.4% NCT03099174 · Phase 1 · registry result, not featured evidence · combination 160 mg + 1 mg fatigue 60% decreased appetite 50% nausea 45% NCT01597193 · Phase 1 · registry result, not featured evidence · combination creatinine increase 13.3% nausea 13.3% thrombocytopenia 13.3% NCT01720602 · Phase na · registry result, not featured evidence · combination diarrhea 40% fatigue 40% hot flashes 40% NCT01004744 · Phase na · registry result, not featured evidence | i arthralgia 9% vaginal haemorrhage 5.9% NCT01176916 · Phase 4 · registry result, not featured evidence show 35 more resultsdiarrhoea 44.9% fatigue 44.9% cough 36.7% NCT01743560 · Phase 4 · registry result, not featured evidence · combination lethargy 56.1% arthralgia 46.4% vomiting 38.4% NCT00253422 · Phase 3 · registry result, not featured evidence neutrophil count decreased 62.7% fatigue 55.3% hypertension 34% NCT02028507 · Phase 3 · registry result, not featured evidence · combination hot flashes 40.2% (placebo 31.9%) pain joint 29.7% (placebo 27%) fatigue 23.4% (placebo 20.7%) NCT00083174 · Phase 3 · registry result, not featured evidence hot flush 31.3% arthralgia 23.8% fatigue 16.4% NCT00036270 · Phase 3 · registry result, not featured evidence fatigue 90% nausea 90% white blood cell decreased 90% NCT02648477 · Phase 2 · registry result, not featured evidence · combination fatigue 75% alkaline phosphatase increased 50% aspartate aminotransferase increased 45% NCT02648477 · Phase 2 · registry result, not featured evidence · combination stomatitis 47.5% (placebo 49.6%) anaemia 39.6% (placebo 28.8%) decreased appetite 34.5% (placebo 25.2%) NCT02258451 · Phase 2 · registry result, not featured evidence · combination hot flashes 66.7% blood glucose increased 61.1% aspartate aminotransferase increased 58.3% NCT00810797 · Phase 2 · registry result, not featured evidence nausea 21.2% fatigue 20.2% vomiting 18.3% NCT01381874 · Phase 2 · registry result, not featured evidence · combination fatigue 27.6% nausea 24.1% hypokalaemia 21.8% NCT01381874 · Phase 2 · registry result, not featured evidence · combination 5 mg + Exemestane nausea 100% stomatitis 83.3% fatigue 66.7% NCT02049957 · Phase 2 · registry result, not featured evidence · combination 4 mg + Exemestane diarrhoea 66.7% fatigue 66.7% nausea 50% NCT02049957 · Phase 2 · registry result, not featured evidence · combination 4 mg + Exemestane fatigue 45.7% hyperglycaemia 45.7% nausea 42.9% NCT02049957 · Phase 2 · registry result, not featured evidence · combination 4 mg + Exemestane nausea 53.5% fatigue 44.2% diarrhoea 39.5% NCT02049957 · Phase 2 · registry result, not featured evidence · combination 3 mg + Exemestane dyspepsia 100% abdominal pain 66.7% arthralgia 66.7% NCT02049957 · Phase 2 · registry result, not featured evidence · combination nausea 36.7% (placebo 30.3%) diarrhoea 31.6% (placebo 9.2%) asthenia 26.6% (placebo 10.5%) NCT00767520 · Phase 2 · registry result, not featured evidence · combination hot flashes 33.3% arthralgia 31% fatigue 11.9% NCT00073073 · Phase 2 · registry result, not featured evidence cough 25% dizziness 25% dyspnoea 25% NCT03280563 · Phase 1/2 · registry result, not featured evidence · combination 125mg mucositis oral 100% neutrophil count decreased 100% platelet count decreased 100% NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination 100mg mucositis oral 100% neutrophil count decreased 83.3% fatigue 50% NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination 100mg mucositis oral 96.9% neutrophil count decreased 87.5% fatigue 65.6% NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination 80mg bd 1w/1w + Ex 25mg dry mouth 58.3% (placebo 0%) alopecia 50% (placebo 0%) dysgeusia 50% (placebo 0%) NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination 80mg bd 2w/1w + Ex 25mg dysgeusia 66.7% (placebo 0%) alopecia 55.6% (placebo 0%) dry mouth 55.6% (placebo 0%) NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination 80mg bd Cont + Ex 25mg alopecia 100% (placebo 0%) dry mouth 80% (placebo 0%) diarrhoea 60% (placebo 0%) NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination 40mg bd Cont + Ex 25mg constipation 80% (placebo 0%) alopecia 60% (placebo 0%) dry mouth 60% (placebo 0%) NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination dry mouth 80% (placebo 0%) alopecia 40% (placebo 0%) asthenia 40% (placebo 0%) NCT01202591 · Phase 1/2 · registry result, not featured evidence · combination rash maculo-papular 33.3% abdominal pain 0% alanine aminotransferase increased 0% NCT01870505 · Phase 1 · registry result, not featured evidence · combination rash maculo-papular 50% abdominal pain 25% alkaline phosphatase increased 25% NCT01870505 · Phase 1 · registry result, not featured evidence · combination aspartate aminotransferase increased 28.6% abdominal pain 14.3% blood bilirubin increased 14.3% NCT01870505 · Phase 1 · registry result, not featured evidence · combination rash maculo-papular 33.3% confusion 16.7% lymphocyte count decreased 16.7% NCT01870505 · Phase 1 · registry result, not featured evidence · combination lymphocyte count decreased 33.3% rash maculo-papular 33.3% anemia 16.7% NCT01870505 · Phase 1 · registry result, not featured evidence · combination abdominal pain 0% alanine aminotransferase increased 0% alkaline phosphatase increased 0% NCT01870505 · Phase 1 · registry result, not featured evidence · combination aspartate aminotransferase increased 33.3% rash maculo-papular 33.3% alkaline phosphatase increased 16.7% NCT01870505 · Phase 1 · registry result, not featured evidence · combination lymphocyte count decreased 42.9% neutrophil count decreased 42.9% white blood cell decreased 42.9% NCT01870505 · Phase 1 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bThe assessment timepoint is not available for both results.
- cThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- dTrial phases differ: Phase 2 versus Phase 3.
- eTreatment context has not been resolved for both arms.
- fPopulation context differs: eligible sex differs (ALL versus FEMALE).
- gTrial phases differ: Phase 2 versus Phase 4.
- hPopulation comparability has not been reviewed for these studies.
- iPopulation comparability has not been reviewed for 39 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Anastrozole
show 1 more result
show 2 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 16 more results
+ 7 further endpoints in the CSV export.
Exemestane
show 3 more results
show 3 more results
show 2 more results
+ 43 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Anastrozole's landscape · Exemestane's landscape